Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • BIOBUSINESS BRIEFS

PIP5K1A: a potential target for cancers with KRAS or TP53 mutations

  1. Michael P. East

    1. Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Tuomo Laitinen

    1. School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Christopher R. M. Asquith

    1. Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Phospholipids have important roles in a diverse array of cellular functions and are tightly regulated by lipid kinases and phosphatases. Some of these enzymes have been extensively studied, such as phosphoinositide 3-kinase (PI3K); aberrant activation of the PI3K–AKT signalling pathway is one of the most prevalent drivers in human cancers, and many drug development programmes have targeted PI3K, leading to four approved drugs. However, other lipid kinases remain poorly characterized although they could also have therapeutic potential in cancer. Here, we focus on one such kinase, PIP5K1A.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 436 (2020)

doi: https://doi.org/10.1038/d41573-020-00067-3

Acknowledgements

This article is part of a series from the NIH Common Fund Illuminating the Druggable Genome (IDG) programme. The goal of IDG is to catalyse research on understudied proteins from druggable gene families by providing reagents, phenotypes and a mineable data base; focusing on GPCRs, kinases and ion channels. For more information, see https://druggablegenome.net/

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links